Diabetic Retinopathy

  • Joseph A. Murphy
  • Firas M. Rahhal


Diabetic retinopathy (DR) is the leading cause of blindness in working-age Americans.l It accounts for 12% of cases of new blindness in the United States each year.2 Of the 12 to 16 million Americans who have diabetes mellitus (DM), it is estimated that 700,000 have proliferative diabetic retinopathy (PDR) and 325,000 have macular edema3 —themost significant forms of sight — threatening DR. Patients who have diabetic retinopathy are 29 times more likely to be blind than non diabetic persons.3 Each year, 25,000 Americans are blinded by DR. In 90% of these cases, early detection and timely management might have prevented visual loss from DR.4 Given these facts, it is obvious that the public health impact of DR is tremendous, and our efforts to better understand this potentially devastating complication of diabetes must continue and, indeed, increase so that improved treatments and preventive measures can be developed.


Vascular Endothelial Growth Factor Diabetic Retinopathy Proliferative Diabetic Retinopathy Central Retinal Vein Occlusion United Kingdom Prospective Diabetes Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kahn HA and Hiller R. Blindness caused by diabetic retinopathy. Am J Ophthalmol 78 (1): 58–67, 1974.PubMedGoogle Scholar
  2. 2.
    Vision Problems in the US: A Statistical Analysis. New York, National Society to Prevent Blindness, 1980.Google Scholar
  3. 3.
    Flynn HW, Smiddy WE, ed. Diabetes and ocular disease: past, present, and future therapies. Ophthalmology Monographs. Vol. 14, Am Acad Ophthal 334, 2000.Google Scholar
  4. 4.
    Ferris FL 3rd. How effective are treatments for diabetic retinopathy? Jama 269 (10): 1290–1, 1993.PubMedCrossRefGoogle Scholar
  5. 5.
    Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 7: 251–266, 1922.Google Scholar
  6. 6.
    Meyer-Schwickerath G. Light coagulation. St. Louis: Mosby - Yearbook, Inc., 1960.Google Scholar
  7. 7.
    Klein R et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102 (4): 520–526, 1984.PubMedCrossRefGoogle Scholar
  8. 8.
    Klein R et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102 (4): 527–532, 1984.PubMedCrossRefGoogle Scholar
  9. 9.
    Klein R et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91 (12): 146–474, 1984.Google Scholar
  10. 10.
    Klein R et al. Retinopathy in young-onset diabetic patients. Diabetes Care 8 (4): 311–5, 1985.PubMedCrossRefGoogle Scholar
  11. 11.
    Klein R et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260 (19): 2864–71, 1988.PubMedCrossRefGoogle Scholar
  12. 12.
    Kostraba JN et al. Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care 12 (10): 686–93, 1989.PubMedCrossRefGoogle Scholar
  13. 13.
    Sjolie AK. Ocular complications in insulin treated diabetes mellitus. An epidemiological study. Acta Ophthalmol Suppl 172: 1–77, 1985.PubMedGoogle Scholar
  14. 14.
    Palmberg P et al. The natural history of retinopathy in insulin-dependent juvenile-onset diabetes. Ophthalmology 88 (7): 613–8, 1981.PubMedGoogle Scholar
  15. 15.
    Frank RN et al. Retinopathy in juvenile-onset type I diabetes of short duration. Diabetes 31 (10): 874–82, 1982.PubMedCrossRefGoogle Scholar
  16. 16.
    Frank RN et al. Retinopathy in juvenile-onset diabetes of short duration. Ophthalmology 87 (1): 1–9, 1980.PubMedGoogle Scholar
  17. 17.
    Dwyer MS et al. Incidence of diabetic retinopathy and blindness: a population-based study in Rochester, Minnesota. Diabetes Care 8 (4): 316–22, 1985.PubMedCrossRefGoogle Scholar
  18. 18.
    Yanko L et al. Prevalence and 15-year incidence of retinopathy and associated characteristics in middle-aged and elderly diabetic men. Brit J Ophthalmol 67 (11): p. 759–65, 1983.CrossRefGoogle Scholar
  19. 19.
    Aiello LM et al. Diabetic retinopathy in Joslin Clinic patients with adult-onset diabetes. Ophthalmology 88 (7): 619–23, 1981.PubMedGoogle Scholar
  20. 20.
    Klein R et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 149 (11): 2427–32, 1989.PubMedCrossRefGoogle Scholar
  21. 21.
    Klein BE, SE Moss, and Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 13 (1): p. 34–40, 1990.PubMedCrossRefGoogle Scholar
  22. 22.
    Knowler WC, Bennett PH, and Ballintine EJ. Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N Engl J Med 302 (12): 645–50, 1980.PubMedCrossRefGoogle Scholar
  23. 23.
    Kornerup T. Studies in diabetic retinopathy. Acta Med Scand 153: 81–101, 1955.PubMedCrossRefGoogle Scholar
  24. 24.
    Anonymous. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Brit Med J 317 (7160): 703–13, 1998.Google Scholar
  25. 25.
    Janka HU et al. Risk factors for progression of background retinopathy in long-standing IDDM. Diabetes 38 (4): 460–4, 1989.PubMedCrossRefGoogle Scholar
  26. 26.
    Dornan T, JI Mann, and R Turner. Factors protective against retinopathy in insulin-dependent diabetics free of retinopathy for 30 years. Brit Med J (Clin Res Ed) 285 (6348): 1073–1077, 1982.CrossRefGoogle Scholar
  27. 27.
    Gray RS et al. HLA antigens and other risk factors in the development of retinopathy in type 1 diabetes. Brit J Ophthalmol 66 (5): 280–285, 1982.CrossRefGoogle Scholar
  28. 28.
    Jerneld B and P Algvere. Proteinuria and blood glucose levels in a population with diabetic retinopathy. Am J Ophthalmol 104 (3): p. 28–39, 1987.Google Scholar
  29. 29.
    Young RJ et al. Alcohol: another risk factor for diabetic retinopathy? Brit Med J (Clin Res Ed) 288 (6423): 1035–1037, 1984.CrossRefGoogle Scholar
  30. 30.
    Barnett AH et al. Microalbuminuria and diabetic retinopathy. Lancet 1 (8419): 53–54, 1985.PubMedCrossRefGoogle Scholar
  31. 31.
    Microalbuminuria predicts proliferative diabetic retinopathy. Lancet 1 (8444): p. 1512–1513, 1985.Google Scholar
  32. 32.
    Nelson RG et al. Proliferative retinopathy in NIDDM. Incidence and risk factors in Pima Indians. Diabetes 38 (4): 435–440, 1989.PubMedCrossRefGoogle Scholar
  33. 33.
    Feldman JN, Beyer MM, et al. Prevalence of diabetic nephropathy at time of treatment for diabetic retinopathy. In: Diabetic Renal - Retinal Syndrome, ed. L.E.F. Firedman EA. Vol 2., New York: Grune Stratton. 9, 1982.Google Scholar
  34. 34.
    Becker B. Diabetes and glaucoma. Vascular complications of diabetes mellitus, ed. K.S.a.K. WM. St Louis: Mosby - Yearbook, Inc., 1967.Google Scholar
  35. 35.
    Dibble CM et al. Effect of pregnancy on diabetic retinopathy. Obstet Gynecol 59 (6): 699–704, 1982.PubMedGoogle Scholar
  36. 36.
    Ohrt V. The influence of pregnancy on diabetic retinopathy with special regard to the reversible changes shown in 100 pregnancies. Acta Ophthalmol (Copenh) 62 (4): 603–616, 1984.CrossRefGoogle Scholar
  37. 37.
    Moloney JB, Drury MI. The effect of pregnancy on the natural course of diabetic retinopathy. Am J Ophthalmol 93 (6): 745–756, 1982.PubMedGoogle Scholar
  38. 38.
    Laatikainen L et al. Occurrence and prognostic significance of retinopathy in diabetic pregnancy. Metab Pediatr Ophthalmol 4 (4): 1915, 1980.Google Scholar
  39. 39.
    Sinclair SH et al. Macular edema and pregnancy in insulin-dependent diabetes. Am J Ophthalmol 97 (2): 154–167, 1984.PubMedGoogle Scholar
  40. 40.
    Phelps RL et al. Changes in diabetic retinopathy during pregnancy. Correlations with regulation of hyperglycemia. Arch Ophthalmol 104 (12): 1806–1810, 1986.PubMedCrossRefGoogle Scholar
  41. 41.
    Bloodworth J. Diabetic microangiopathy. Diabetes 12: 99, 1963.PubMedGoogle Scholar
  42. 42.
    Toussaint D, Dustin P. Electron micorscopy of normal and diabetic retinal capillaries. Arch Ophthalm 70: 96, 1963.CrossRefGoogle Scholar
  43. 43.
    Ashton N. Vascular basement membrane changes in diabetic retinopathy. Br J Ophthal 58: 344, 1974.CrossRefGoogle Scholar
  44. 44.
    Apple DJ, Rabb MF. Ocular Pathology. Third ed. St Louis: C.V. Mosby. 560, 1985.Google Scholar
  45. 45.
    Kristinsson JK, Gottfredsdottir MS, Stefansson E. Retinal vessel dilatation and elongation precedes diabetic macular oedema. Br J Ophthalmol 81 (4): p. 274–278, 1997.PubMedCrossRefGoogle Scholar
  46. 46.
    Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes-Metabolism Reviews 13 (1): 37–50, 1997.PubMedCrossRefGoogle Scholar
  47. 47.
    Pierce EA et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad of Sci 92 (3): 905–909, 1995.CrossRefGoogle Scholar
  48. 48.
    Senger DR et al. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Research 50 (6): 1774–1778, 1990.PubMedGoogle Scholar
  49. 49.
    Plate KH et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 (6398): 845–848, 1992.PubMedCrossRefGoogle Scholar
  50. 50.
    Olander JV, Connolly DT, DeLarco JE. Specific binding of vascular permeability factor to endothelial cells. Biochem Biophysic Res Com 175 (1): 68–76, 1991.CrossRefGoogle Scholar
  51. 51.
    Houck KA et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267 (36): 26031–26037, 1992.PubMedGoogle Scholar
  52. 52.
    Aiello LP et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (22): 1480–1487, 1994.PubMedCrossRefGoogle Scholar
  53. 53.
    Tolentino MJ et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthal 103 (11): 1820–1828, 1996.Google Scholar
  54. 54.
    Adamis AP et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthal 114 (1): 66–71, 1996.PubMedCrossRefGoogle Scholar
  55. 55.
    Robinson GS et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci 93 (10): 4851–4856, 1996.PubMedCrossRefGoogle Scholar
  56. 56.
    Ways DK and MJ Sheetz. The role of protein kinase C in the development of the complications of diabetes. Vitamins Hormones 60: 149–193, 2000.PubMedCrossRefGoogle Scholar
  57. 57.
    Xia P et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43 (9): 1122–1129, 1994.PubMedCrossRefGoogle Scholar
  58. 58.
    Mazure NM et al. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90 (9): 3322–3331, 1997.PubMedGoogle Scholar
  59. 59.
    Williams B et al. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 46 (9): 1497–1503, 1997.PubMedCrossRefGoogle Scholar
  60. 60.
    Xia P et al. Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Investigation 98 (9): 2018–2026, 1996.CrossRefGoogle Scholar
  61. 61.
    Jirousek MR et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem 39(14):2664–2671, 1996.Google Scholar
  62. 62.
    Ishii H et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. [see comments]. Science 272 (5262): 728–731, 1996.PubMedCrossRefGoogle Scholar
  63. 63.
    Aiello LP et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46 (9): 1473–1480, 1997.PubMedCrossRefGoogle Scholar
  64. 64.
    Danis RP et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Investigative Ophthalmology Visual Science 39 (1): 171–179, 1998.PubMedGoogle Scholar
  65. 65.
    Singh R et al. Advanced glycation end-products: a review. Diabetologia 44 (2): 129–146, 2001.PubMedCrossRefGoogle Scholar
  66. 66.
    Maillard LC. Action des acides amines sur les sucres: formation des melanoides par voie methodique. CR Acad Sci 154: 66–68, 1912.Google Scholar
  67. 67.
    Stitt AW et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol, 150 (2): 523–531, 1997.PubMedGoogle Scholar
  68. 68.
    Clements RS Jr, Robison WG Jr, and Cohen MP. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J Diab Compl 12 (1): 28–33, 1998.CrossRefGoogle Scholar
  69. 69.
    Stitt AW et al. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Molecular Cell Biology Research Communications 3 (6): 380–388, 2000.PubMedCrossRefGoogle Scholar
  70. 70.
    Chakravarthy U et al. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 47 (6): p. 945–952, 1998.PubMedCrossRefGoogle Scholar
  71. 71.
    Gonzalez RG et al. Direct measurement of polyol pathway activity in the ocular lens. Diabetes 33 (2): 196–199, 1984.PubMedCrossRefGoogle Scholar
  72. 72.
    Van den Enden MK et al. Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism. Implications for diabetic retinopathy. [see comments]. Investigative Ophthalmology Visual Science 36 (8): 1675–1685, 1995.PubMedGoogle Scholar
  73. 73.
    Chakrabarti S and Sima AA. Effect of aldose reductase inhibition and insulin treatment on retinal capillary basement membrane thickening in BB rats. Diabetes 38 (9): 1181–1186, 1989.PubMedCrossRefGoogle Scholar
  74. 74.
    Anonymous. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch Ophthal 108 (9): 1234–1244, 1990.Google Scholar
  75. 75.
    Nishikawa T et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 (6779): 787–790, 2000.PubMedCrossRefGoogle Scholar
  76. 76.
    Coupland SG. A comparison of oscillatory potential and pattern electroretinogram measures in diabetic retinopathy. Doc Ophthalmol 66 (3): 207–218, 1987.PubMedCrossRefGoogle Scholar
  77. 77.
    Sokol S et al. Contrast sensitivity in diabetics with and without background retinopathy. Arch Ophthalmol 103 (1): 51–54, 1985.PubMedCrossRefGoogle Scholar
  78. 78.
    Preferred Practice Pattern, Diabetic Retinopathy. American Academy of Ophthalmology: San Francisco. p. 36., 1998.Google Scholar
  79. 79.
    Panoptic ophthalmoscope. Welch Allyn, 2001.Google Scholar
  80. 80.
    Anonymous. Preliminary report on effects of photocoagulation therapy. The Diabetic retinopathy study research group. Am J Ophthal 81 (4): 383–396, 1976.Google Scholar
  81. 81.
    Kertes PJ, Conway MD, ed. Clinical trials in ophthalmology: a summary and practice guide. Williams and Wilkins: Baltimore, 1998.Google Scholar
  82. 82.
    Anonymous. Diabetic retinopathy study research group: Design, methods, and baseline results. DRS report Number 6. Invest Ophthalmol Vis Sci 21: 149–201, 1981.Google Scholar
  83. 83.
    Anonymous. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 88 (7): 583–600, 1981.Google Scholar
  84. 84.
    Anonymous. Early treatment diabetic retinopathy study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 98 (Suppl 5): 741–756, 1991.Google Scholar
  85. 85.
    Anonymous. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early treatment diabetic retinopathy study research group. Ophthalmology 98 (Suppl 5): 766–785, 1991.Google Scholar
  86. 86.
    Anonymous. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early treatment diabetic retinopathy study research group. Ophthalmology 98 (Suppl 5): 757–765, 1991.Google Scholar
  87. 87.
    Anonymous. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. ETDRS Investigators. JAMA 268 (10): 1292–1300, 1992.Google Scholar
  88. 88.
    Machemer R et al. Vitrectomy: a pars plana approach. Transactions–American Academy of Ophthalmology Otolaryngology 75 (4): 813–820, 1971.PubMedGoogle Scholar
  89. 89.
    Anonymous. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial-Diabetic retinopathy vitrectomy study report 3. The Diabetic Retinopathy vitrectomy study research group. Ophthalmology 95 (10): 1307–1320, 1998.Google Scholar
  90. 90.
    Anonymous. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic retinopathy vitrectomy study report 5. [erratum appears in Arch Ophthalmol Oct; 108(10):1452]. Arch Ophthal 108 (7): 958–964, 1990.Google Scholar
  91. 91.
    Klein R et al. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 154 (19): 2169–2178, 1994.PubMedCrossRefGoogle Scholar
  92. 92.
    Klein R and Moss S. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 155 (7): 745–754, 1995.PubMedCrossRefGoogle Scholar
  93. 93.
    Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. [erratum appears in Lancet 1999 Aug 14;354(9178):602]. Lancet 352 (9131): 837–853, 1998.Google Scholar

On-Line Resources

  1. Diabetic Retinopathy: Epidemiology, Diagnosis and Management,
  2. Diabetes in America, Diabetes in America, 2nd Edition, is a 733-page compilation and assessment of epidemiologic, public health, and clinical data on diabetes and its complications in the United States.

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Joseph A. Murphy
  • Firas M. Rahhal

There are no affiliations available

Personalised recommendations